Het effect van beweging op de bloeddoorstroming in de hersenen bij patiënten met vasculaire cognitieve stoornisse
- Conditions
- Vascular cognitive impairment, Aerobic exercise,Cerebral blood flow, Arterial spin labeling
- Registration Number
- NL-OMON22385
- Lead Sponsor
- VU University Medical CenterUniversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 80
•Age: ≥50 years.
•Cognitive complaints
•Diagnosis of dementia.
•Contra-indication for MRI or unable to undergo MRI protocol due to a physical condition.
•Participation in aerobic exercise program (moderate-to-hard intensity) ≥ twice weekly on a regular basis.
•Major neurological (e.g. Parkinson’s disease, multiple sclerosis), cardiac (e.g. heart-failure, severe aorta stenosis, cardiac rhythm disturbances) or other medical disease that affects cognition and mobility and constitutes a contra-indication to perform aerobic exercise training.
•Clinically significant peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility.
•Other neurological diagnosis, such as severe traumatic brain injury, or major psychiatric disorder, such as psychosis, schizophrenia, severe personality disorder or depression with vital signs, alcohol abuse or other substances, that could affect cognitive performance during neuropsychological assessment.
•Participation in on-going trials for therapeutic interventions including randomized controlled trials and clinical trials investigating medicinal products.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method •Change in cerebral blood flow (CBF), measured with Arterial Spin-Labeling-Magnetic Resonance Imaging (ASL-MRI).
- Secondary Outcome Measures
Name Time Method •Change in cognitive functions on neuropsychological testing;<br>•Change in brain structure; <br>•Change in physical fitness; <br>•Change in blood biomarkers; <br>•Change in (i)ADL, neuropsychiatric measures and quality of life; <br /><br>•Change in cerebral autoregulation; <br /><br>•Change in cerebral vasomotor reactivity; <br>